IP Verse

Janssen Biotech competitive analysis

Latest publications and patents of Janssen Biotech New

Explore the latest publications and patents granted to Janssen Biotech, showcasing their recent innovations and technological advancements.

Last updated on: Sep 30, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Janssen Biotech

EP3883606
Nov 20, 2024Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 AntibodyGranted And Under Opposition
EP3880824
Jul 24, 2024Control Of Trace Metals During Production Of Anti-Cd38 AntibodiesGranted And Under Opposition
EP2970980
Jul 27, 2022Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant ProteinsPatent Maintained As Amended
EP3827845
Mar 30, 2022Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their UsesGranted And Under Opposition
EP3370770
Jan 20, 2021Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their UsesRevoked
EP2938724
Oct 28, 2020Culturing Of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine CellsGranted And Under Opposition
EP3219328
Jun 17, 2020Human Anti-Il-23 Antibodies, Compositions, Method And UsesRevoked
EP2569419
Mar 20, 2019Differentiation Of Human Embryonic Stem CellsGranted And Under Opposition
EP2669366
Jan 31, 2018Pluripotent CellsNo Opposition Filed Within Time Limit
EP2611910
Jan 17, 2018Differentiation Of Human Embryonic Stem CellsNo Opposition Filed Within Time Limit

Latest oppositions filed by Janssen Biotech

Explore patent oppositions filed by Janssen Biotech against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3177645
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERMar 16, 2021
EP2780374
Binding Molecules For Bcma And Cd3AMGENApr 14, 2020
EP2780375
Binding Molecules For Bcma And Cd3AMGENApr 14, 2020
EP2647707
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAMay 24, 2019
EP1810026
B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of CancerMAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHJan 18, 2019
EP3209309
Compositions Comprising Bacterial StrainsCJ BIOSCIENCEDec 14, 2018

Latest patents of Janssen Biotech opposed by its competitors

Explore Janssen Biotech's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3883606
Nov 20, 2024Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody5
EP3880824
Jul 24, 2024Control Of Trace Metals During Production Of Anti-Cd38 Antibodies1
EP2970980
Jul 27, 2022Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins1
EP3827845
Mar 30, 2022Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses5
EP3370770
Jan 20, 2021Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses3
EP2938724
Oct 28, 2020Culturing Of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells1
EP3219328
Jun 17, 2020Human Anti-Il-23 Antibodies, Compositions, Method And Uses2
EP2569419
Mar 20, 2019Differentiation Of Human Embryonic Stem Cells1

Latest PTAB cases involving Janssen Biotech

Discover the latest PTAB cases involving Janssen Biotech, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 6, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Janssen Biotech

IPR2023-01444Nov 22, 2023BIOCON BIOLOGICSJANSSEN BIOTECHTerminated-Settled
IPR2023-01103Jun 21, 2023SAMSUNG BIOEPISJANSSEN BIOTECHTerminated-Settled
IPR2021-01484Sep 9, 2021JANSSEN BIOTECHTHE UNITED STATES OF AMERICAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Janssen Biotech with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
JANSSEN BIOTECH61912Balanced
AMGEN8132811Defensive
AMGEN RESEARCH MUNICH - 29 - - Non-Active
BIOCON BIOLOGICS1 - 3 - Highly Aggressive